Top Page
Polarean Imaging
(LSE:POLX)
Polarean Imaging (POLX) vs. iShares MSCI United Kingdom ETF (EWC)
Polarean Imaging Business Overview & Revenue Model
Polarean Imaging Earnings Call Summary
Polarean Imaging Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.42M | 890.93K | 1.03M | 1.19M | 1.06M |
| Gross Profit | 358.61K | 335.48K | 348.28K | 508.02K | 710.47K |
| EBITDA | -5.92M | -10.93M | -12.84M | -13.06M | -5.73M |
| Net Income | -6.68M | -11.88M | -13.91M | -14.02M | -6.55M |
Balance Sheet | |||||
| Total Assets | 15.79M | 10.88M | 22.54M | 34.53M | 10.88M |
| Cash, Cash Equivalents and Short-Term Investments | 12.11M | 6.17M | 16.45M | 28.87M | 6.28M |
| Total Debt | 503.79K | 216.69K | 358.84K | 489.79K | 221.43K |
| Total Liabilities | 3.65M | 2.58M | 3.23M | 2.79M | 2.15M |
| Stockholders Equity | 12.14M | 8.30M | 19.30M | 31.74M | 8.73M |
Cash Flow | |||||
| Free Cash Flow | -4.33M | -10.51M | -12.32M | -12.79M | -5.86M |
| Operating Cash Flow | -4.17M | -10.43M | -12.26M | -12.25M | -5.79M |
| Investing Cash Flow | -154.66K | 219.98K | -63.95K | -541.45K | -65.53K |
| Financing Cash Flow | 9.02M | -140.04K | 147.62K | 35.07M | 10.18M |
Polarean Imaging Technical Analysis
Polarean Imaging Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £5.16M | -4.90 | -5.41% | ― | -20.31% | -19.35% | |
47 Neutral | £20.02M | -6.04 | -101.07% | ― | ― | 45.70% | |
44 Neutral | £18.16M | -1.59 | -51.63% | ― | 31.78% | 10.27% | |
42 Neutral | $4.83M | ― | -80.95% | ― | 33.86% | 76.08% | |
42 Neutral | £46.40M | -1.88 | ― | ― | ― | ― |
Polarean Imaging Corporate Events
Polarean Imaging PLC is conducting a strategic review of its future direction and organizational structure due to challenges in the UK public market for small-cap MedTech companies, including undervaluation and limited liquidity. The company is considering options such as transitioning to a private company to reduce operational expenses and gain strategic flexibility, which may involve delisting from AIM. This move aims to maximize shareholder value and provide better access to capital, although no final decision has been made. Polarean remains committed to advancing its mission in pulmonary medicine while this review is ongoing.
The most recent analyst rating on (GB:POLX) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
Polarean Imaging Plc’s recent earnings call presented a mixed sentiment, highlighting both achievements and challenges. While the company reported significant increases in sales quotes and new orders, it also faced disappointing revenue results and market headwinds. These factors are impacting the company’s performance, despite positive developments in international expansion and consumable growth.
Polarean Imaging has expanded its agreement with Ascend Imaging to enhance its commercial reach in the US, increasing its coverage from four to 19 states. This strategic move aims to accelerate the adoption of Polarean’s Xenon MRI platform, which is gaining recognition for its value in functional lung imaging, thus potentially improving patient outcomes and expanding market presence.
The most recent analyst rating on (GB:POLX) stock is a Buy with a £0.04 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
Polarean Imaging has entered into a new supply agreement with the University of Virginia Health to implement full clinical Xenon MRI capabilities. This partnership marks a significant step in advancing pulmonary imaging, as UVA Health, a leader in Xenon MRI research, prepares to launch its first clinical Xenon MRI scan. The collaboration aims to enhance the evaluation and treatment of lung diseases, aligning with Polarean’s mission to provide critical imaging solutions for chronic lung disease.
The most recent analyst rating on (GB:POLX) stock is a Buy with a £0.04 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
Polarean Imaging has announced the sale of its Xenon MRI System to the National Institutes of Health (NIH) Clinical Center, marking the first direct purchase by the NIH. This acquisition will enhance research capabilities in lung imaging and respiratory conditions, positioning Polarean as a leader in innovative MRI techniques. The collaboration with the NIH is expected to advance studies on lung diseases and improve patient care, reinforcing Polarean’s impact on the medical imaging industry.
The most recent analyst rating on (GB:POLX) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
Polarean Imaging has reported its interim results for the first half of 2025, highlighting a challenging market environment due to reductions in NIH grant funding and Medicaid cuts under the US One Big Beautiful Bill Act. Despite these challenges, the company saw a 36% increase in consumable sales, though no Xenon MRI systems were sold in the period. The company has expanded its FDA approvals and partnerships, including a strategic collaboration with Philips and a distribution agreement in Taiwan, which are expected to enhance its market presence. However, due to the current market uncertainties, Polarean has lowered its revenue guidance for 2025 but remains optimistic about resuming sales growth in 2026.
The most recent analyst rating on (GB:POLX) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
Polarean Imaging PLC, a leader in advanced MRI technology for lung function, announced it will release its half-year results for the period ending 30 June 2025 on 25 September 2025. The company will host a live online presentation for shareholders, providing an opportunity for interaction and questions. This announcement highlights Polarean’s ongoing commitment to transparency and engagement with its stakeholders, reinforcing its position in the medical imaging industry.
The most recent analyst rating on (GB:POLX) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
Polarean Imaging plc has submitted a new Phase III clinical trial protocol to the FDA to expand the indication of its XENOVIEW® contrast agent to include quantitative gas-exchange imaging. This expansion aims to enhance the clinical utility of XENOVIEW by enabling comprehensive lung function assessment, which could significantly impact the diagnosis and treatment of various pulmonary diseases. The FDA’s review of this protocol is expected to conclude by Q4 2025, marking a critical milestone in Polarean’s growth strategy and its mission to transform pulmonary imaging.
The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.